Phaseline

Companies › CNS Pharmaceuticals

CNS Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Berubicin
DNA topoisomerase II inhibitor
TOP2A, TOP2BPhase 2Glioblastoma Multiforme, Adult–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04762069BerubicinPhase 2Glioblastoma Multiforme, AdultOncologyApr 2026

From the company's SEC filings

Cash of $20m on 2026-06-30; operating cash outflow about $17m a year; runway about 14 months at that burn, to Sep 2027

Press releases filed as 8-K in the last year:

Targets

TOP2A (1) TOP2B (1)

Companies with the same targets

SkinJect CSPC ZhongQi Pharmaceutical Technology ImmunityBio

Companies built like this

CEBIOTEX Targeted Therapy Technologies Allarity Therapeutics Processa Pharmaceuticals Moleculin Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.